Blockchain Registration Transaction Record

Cartilage Regeneration: Regentis Advances GelrinC Amid Industry Validation

Regentis Biomaterials advances GelrinC, a hydrogel cartilage implant, as Smith+Nephew's acquisition of CartiHeal validates the regenerative orthopedics market.

This development matters because cartilage damage affects millions globally, often leading to chronic pain and joint replacement. GelrinC's off-the-shelf, cell-free approach could simplify treatment, reduce costs, and improve outcomes. The acquisition of CartiHeal by Smith+Nephew confirms major orthopedic companies see high value in regenerative solutions, signaling that effective therapies like GelrinC may soon transform patient care and reduce the burden of joint disease.